Larson Financial Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.47M | Buy |
310,250
+200,269
| +182% | +$5.24M | 0.2% | 89 |
|
|
2026
Q1 | $3.09M | Sell |
109,981
-25,535
| -19% | -$680K | 0.1% | 180 |
|
|
2025
Q4 | $3.37M | Buy |
135,516
+4,109
| +3% | +$104K | 0.11% | 161 |
|
|
2025
Q3 | $3.35M | Buy |
131,407
+5,945
| +5% | +$147K | 0.12% | 159 |
|
|
2025
Q2 | $3.04M | Buy |
125,462
+21,391
| +21% | +$499K | 0.12% | 160 |
|
|
2025
Q1 | $2.64M | Buy |
104,071
+7,405
| +8% | +$194K | 0.12% | 152 |
|
|
2024
Q4 | $2.56M | Buy |
96,666
+7,377
| +8% | +$200K | 0.13% | 139 |
|
|
2024
Q3 | $2.58M | Buy |
89,289
+29,862
| +50% | +$871K | 0.15% | 128 |
|
|
2024
Q2 | $1.66M | Buy |
59,427
+25,658
| +76% | +$706K | 0.11% | 151 |
|
|
2024
Q1 | $937K | Buy |
33,769
+11,101
| +49% | +$308K | 0.07% | 173 |
|
|
2023
Q4 | $653K | Buy |
22,668
+2,325
| +11% | +$70.3K | 0.06% | 187 |
|
|
2023
Q3 | $675K | Buy |
20,343
+3,639
| +22% | +$129K | 0.07% | 174 |
|
|
2023
Q2 | $613K | Sell |
16,704
-2,468
| -13% | -$96.1K | 0.06% | 178 |
|
|
2023
Q1 | $782K | Buy |
19,172
+371
| +2% | +$16K | 0.09% | 169 |
|
|
2022
Q4 | $963K | Buy |
18,801
+4,041
| +27% | +$194K | 0.12% | 151 |
|
|
2022
Q3 | $646K | Sell |
14,760
-936
| -6% | -$45.5K | 0.09% | 151 |
|
|
2022
Q2 | $823K | Buy |
15,696
+3,885
| +33% | +$198K | 0.14% | 75 |
|
|
2022
Q1 | $611K | Sell |
11,811
-3,304
| -22% | -$171K | 0.1% | 95 |
|
|
2021
Q4 | $893K | Buy |
15,115
+2,884
| +24% | +$143K | 0.14% | 73 |
|
|
2021
Q3 | $526K | Buy |
12,231
+221
| +2% | +$9.79K | 0.1% | 80 |
|
|
2021
Q2 | $470K | Sell |
12,010
-564
| -4% | -$21.9K | 0.11% | 76 |
|
|
2021
Q1 | $456K | Buy |
12,574
+517
| +4% | +$18.4K | 0.13% | 67 |
|
|
2020
Q4 | $444K | Buy |
12,057
+2,069
| +21% | +$75.9K | 0.15% | 62 |
|
|
2020
Q3 | $348K | Sell |
9,988
-1,339
| -12% | -$46.9K | 0.14% | 66 |
|
|
2020
Q2 | $351K | Buy |
11,327
+859
| +8% | +$29.2K | 0.17% | 71 |
|
|
2020
Q1 | $324K | Buy |
10,468
+4,254
| +68% | +$145K | 0.2% | 63 |
|
|
2019
Q4 | $231K | Sell |
6,214
-821
| -12% | -$29.2K | 0.13% | 72 |
|
|
2019
Q3 | $240K | Buy |
7,035
+1,542
| +28% | +$56.1K | 0.16% | 67 |
|
|
2019
Q2 | $226K | Buy |
5,493
+708
| +15% | +$28.1K | 0.17% | 53 |
|
|
2019
Q1 | $193K | Sell |
4,785
-546
| -10% | -$21.9K | 0.15% | 57 |
|
|
2018
Q4 | $221K | Buy |
5,331
+178
| +3% | +$7.39K | 0.2% | 50 |
|
|
2018
Q3 | $215K | Buy |
+5,153
| New | +$198K | 0.25% | 43 |
|
Other funds holding PFE
Larson Financial Group's PFE Position: Q2 2026 in Review
Larson Financial Group increased its Pfizer (PFE) stake by 182% in Q2 2026, buying an estimated $5.24M and bringing the position to 310,250 shares worth $7.47M. The position accounts for 0.2% of the portfolio, ranked #89.
Larson Financial Group first reported a position in PFE in Q3 2018 and has held it in 32 quarters since. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Larson Financial Group held 310,250 shares of Pfizer worth $7.47M as of Q2 2026.
- Larson Financial Group bought 200,269 Pfizer shares in Q2 2026, an estimated $5.24M.
- Pfizer made up 0.2% of Larson Financial Group's portfolio in Q2 2026, its #89 holding.
- Larson Financial Group first reported a position in Pfizer in Q3 2018 and has held it in 32 quarters since.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.